The Impact of HBV Therapy on Fibrosis and Cirrhosis
Source: The Impact of HBV Therapy on Fibrosis and Cirrhosis

Slideset

The Impact of HBV Therapy on Fibrosis and Cirrhosis

In this downloadable slideset, Jordan J. Feld, MD, MPH, illustrates the key data on optimal management of fibrosis and cirrhosis in HBV.
Format: Microsoft PowerPoint (.ppt)
File size: 546 KB
Date posted: 12/22/2016
  • Decompensated Cirrhosis: My Take on New Treatment Strategies Following AASLD 2015

    Ira M. Jacobson MD - 12/24/2015    2 comments / Last Comment: 1/4/2016
    Despite the variety of highly effective, highly tolerable regimens available for treating HCV, strategies for patients with decompensated liver disease remain challenging.
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016    3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
  • Why I am Encouraged by Data on NASH Management From the 2016 Boston Hepatology Meeting

    Brent A. Neuschwander-Tetri MD - 3/10/2017    
    The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.
  • Hepatitis B Reactivation: Sometimes Scratching the Surface May Be Better Than Getting to the Core

    Jordan J. Feld MD, MPH - 1/24/2017    2 comments / Last Comment: 2/21/2017
    Does the need for HBV reactivation screening vary by the potency of immunosuppressive therapy? Here’s my take.
  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016    1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.